Veijo Hukkanen
 MDPhD


veijo.hukkanen@utu.fi

+358 29 450 4552

Kiinamyllynkatu 10

Turku


ORCID-tunnistehttps://orcid.org/0000-0002-2867-7844





Asiantuntijuusalueet
Virukset; Herpesvirukset; geenihoidot; onkolyyttiset virukset; onkolyyttiset immunoterapiat; viruslääkkeet; virustautien lääkehoidot

Tutkimusyhteisö tai tutkimusaihe
Uudet RNA-välitteiset virusinfektioiden hoidot; Geenihoito ja herpesvirusvektorit

Biografia

Chairperson of the Institute of Microbiology and Pathology (Kliinis-teoreettinen laitos) 2001-2003

Convener and Co-chair of the International Herpesvirus conference IHW2005, Turku, 2005

Professor at the Department of Medical Microbiology, University of Oulu (virology) 2005-2009

Professor at the Department of Virology, University of Turku, 2010-2013

Herpesvirology research 1983-current

Thesis work on neuroimmunology and neurovirology 1978-1982



Tutkimus

Herpes simplex virus (HSV) is a common pathogen of humans, causing a spectrum of infections ranging from cold sores and genital herpes to the serious neonatal herpes infections and encephalitis. However, HSV is also one of the most important oncolytic viruses (destroying cancer cells) and gene therapy vectors. A characteristic feature of HSV is the latent infection in the nervous system, mainly in sensory ganglia. The latent HSV infection is permanent, although recurrencies can be treated with antiviral chemotherapy. Our project develops means for prevention and treatment of virus infection and viral latency. We have established a successful RNA interference approach, using enzymatically produced antiviral siRNA swarms, for control of HSV infection, as a joint project with the premier RNA research laboratory in Finland. 

HSV is a promising backbone for gene therapy vectors, due to its neurotropism, its immune evasion abilities, drug sensitivity and numerous other beneficial properties. An oncolytic HSV has gained approval by the FDA and the European Medicines Agency.  Our team has long-term experience in developing HSV vectors. We construct novel HSV recombinant viruses and study the use of these attenuated viruses in gene therapy of central nervous system diseases. We also develop oncolytic HSV for treatment of cancer. Our research has produced new HSV vectors, from which therapeutic cytokines and trophic factors are expressed.  We improve delivery and targeting methods for HSV gene therapy. 

We elucidate the genetic diversity among HSV strains from natural clinical isolates. We apply NGS sequencing methods suitable for analysis of large DNA viruses, in collaboration with a pioneer laboratory of the field. These studies benefit antiviral development, pathogenesis studies, and virus vector development. We also improve molecular diagnostic methods for the herpes viruses in clinical diseases, having many decades of experience in HSV nucleic acid detection. We collaborate with significant domestic and international research groups. Our project has yielded over 10 doctoral dissertations, in addition to over 20 MSc theses and numerous special projects in fields of biomedicine and other biosciences.



Opetus

I have 4 decades of experience and interest in activating teaching of Virology, to students of medicine and biomedicine. My teaching is based on scientific research.

I have completed the first ever organized training course in University Pedagogics in the University of Turku, and the first organized training course in Medical Pedagogics in the University of Turku.



Julkaisut
  
null
  
null
  
3/6
  
null
  
null
  

  • Herpes simplex and human papilloma virus coinfections in oral mucosa of men-A 6-year follow-up study  (2018)  
    • Journal of Medical Virology
     Mäki Johanna, Paavilainen Henrik, Kero Katja, Hukkanen Veijo, Syrjänen Stina
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Novel activities of safe-in-human broad-spectrum antiviral agents  (2018)  
    • Antiviral Research
     Aleksandr Ianevski, Eva Zusinaite, Suvi Kuivanen, Mårten Strand, Hilde Lysvand, Mona Teppor, Laura Kakkola, Henrik Paavilainen, Mira Laajala, Hannimari Kallio-Kokko, Miia Valkonen, Anu Kantele, Kaidi Telling, Irja Lutsar, Pille Letjuka, Natalja Metelitsa, Valentyn Oksenych, Magnar Bjørås, Svein Arne Nordbø, Uga Dumpis, Astra Vitkauskiene, Christina Öhrmalm, Kåre Bondeson, Anders Bergqvist, Tero Aittokallio, Rebecca J. Cox, Magnus Evander, Veijo Hukkanen, Varpu Marjomaki, Ilkka Julkunen, Olli Vapalahti, Tanel Tenson, Andres Merits, Denis Kainov
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses  (2018)  
    • Molecular Therapy
     Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, Oona Honkasalo, Manlio Fusciello, Beatriz Martins, Leena Ylösmäki, Antti Louna, Sara Feola, Henrik Paavilainen, Karita Peltonen, Veijo Hukkanen, Tapani Viitala, Vincenzo Cerullo
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins  (2017)  
    • Viruses
     Daria Bulanova, Aleksandr Ianevski, Andrii Bugai, Yevhen Akimov, Suvi Kuivanen, Henrik Paavilainen, Laura Kakkola, Jatin Nandania, Laura Turunen, Tiina Ohman, Hanna Ala-Hongisto, Hanna M. Pesonen, Marika S. Kuisma, Anni Honkimaa, Emma L. Walton, Valentyn Oksenych, Martina B. Lorey, Dmitry Guschin, Jungmin Shim, Jinhee Kim, Thoa T. Than, So Young Chang, Veijo Hukkanen, Evgeny Kulesskiy, Varpu S. Marjomaki, Ilkka Julkunen, Tuula A. Nyman, Sampsa Matikainen, Jani S. Saarela, Famara Sane, Didier Hober, Gülsah Gabriel, Jef K. De Brabander, Miika Martikainen, Marc P. Windisch, Ji-Young Min, Roberto Bruzzone, Tero Aittokallio, Markus Vähä-Koskela, Olli Vapalahti, Arto Pulk, Vidya Velagapudi, Denis E. Kainov
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Chromatin organization regulates viral egress dynamics  (2017)  
    • Scientific Reports
     Aho V, Myllys M, Ruokolainen V, Hakanen S, Mäntylä E, Virtanen J, Hukkanen V, Kühn T, Timonen J, Mattila K, Larabell CA, Vihinen-Ranta M
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Regulation of kynurenine biosynthesis during influenza virus infection  (2017)  
    • FEBS Journal
     Gaelings L, Söderholm S, Bugai A, Fu Y, Nandania J, Schepens B, Lorey MB, Tynell J, Vande Ginste L, Le Goffic R, Miller MS, Kuisma M, Marjomäki V, De Brabander J, Matikainen S, Nyman T, Bamford D, Saelens X, Julkunen I, Paavilainen H, Hukkanen V, Velagapudi V, Kainov DE
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • The ERK-1 function is required for HSV-1-mediated G1/S progression in HEP-2 cells and contributes to virus growth  (2017)  
    • Scientific Reports
     Colao I, Pennisi R, Venuti A, Nygårdas M, Heikkilä O, Hukkanen V, Sciortino MT
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Topical treatment of herpes simplex virus infection with enzymatically created siRNA swarm  (2017)  
    • Antiviral Therapy
     Henrik Paavilainen, Jenni Lehtinen, Alesia Romanovskaya, Michaela Nygårdas, Dennis H Bamford, Minna M Poranen, Veijo Hukkanen
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • Herpes simplex virus 1 induces egress channels through marginalized host chromatin  (2016)  
    • Scientific Reports
     Myllys M, Ruokolainen V, Aho V, Smith EA, Hakanen S, Peri P, Salvetti A, Timonen J, Hukkanen V, Larabell CA, Vihinen-Ranta M
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )


  • HSV-1 Infection Modulates the Radioresponse of a HPV16-positive Head and Neck Cancer Cell Line  (2016)  
    • Anticancer Research
     Turunen A, Hukkanen V, Kulmala J, Syrjanen S
    (
    A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



Last updated on